Get the Stockscreener App
3.15
24.02%
0.61
After Hours:
3.12
-0.03
-0.95%
Serina Therapeutics Inc stock is traded at $3.15, with a volume of 10.92M.
It is up +24.02% in the last 24 hours and up +100.64% over the past month.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
See More
Previous Close:
$2.54
Open:
$2.73
24h Volume:
10.92M
Relative Volume:
2.71
Market Cap:
$33.97M
Revenue:
$144.00K
Net Income/Loss:
$-14.50M
P/E Ratio:
-2.1723
EPS:
-1.4501
Net Cash Flow:
$-14.95M
1W Performance:
+115.75%
1M Performance:
+100.64%
6M Performance:
-37.13%
1Y Performance:
-34.38%
1-Day Range:
$2.68
$3.29
1-Week Range:
$1.22
$3.29
52-Week Range:
$1.22
$7.92
Serina Therapeutics Inc Stock (SER) Company Profile
Name
Serina Therapeutics Inc
Sector
Industry
Phone
(256) 327-9630
Address
601 GENOME WAY, HUNTSVILLE
Compare SER vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SER
Serina Therapeutics Inc
|
3.15 | 27.40M | 144.00K | -14.50M | -14.95M | -1.4501 |
VRTX
Vertex Pharmaceuticals Inc
|
451.24 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
736.53 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
681.85 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
306.66 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
143.98 | 29.32B | 606.42M | -1.28B | -997.58M | -6.403 |
Serina Therapeutics Inc Stock (SER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | H.C. Wainwright | Buy |
Serina Therapeutics Inc Stock (SER) Latest News
Serina Therapeutics Inc appoints Greg Bailey as co-chairman of boardSEC filing - marketscreener.com
Serina Therapeutics IncAppoints Greg Bailey As Co-Chairman Of BoardSEC Filing - TradingView
Serina Therapeutics (SER) lines up $30M private placement plus $33.3M warrant upside - Stock Titan
Serina Therapeutics Inc. Faces Stock Volatility Amid Economic Challenges - StocksToTrade
Risk Check: What is the dividend yield of Serina Therapeutics IncEarnings Recap Summary & Daily Profit Focused Stock Screening - baoquankhu1.vn
Serina Therapeutics secures up to $30M in private placement - MSN
Serina Therapeutics Insider Sells $97,500 in Stock - National Today
Serina Therapeutics (SER) stock surges over 39% after hours—here's why - MSN
Top Serina Therapeutics Executive Makes Notable Stock Move - TipRanks
Serina Therapeutics CSO sells $97,500 in shares By Investing.com - Investing.com Canada
Serina Therapeutics (SER) CSO exercises options and sells 39,000 shares - Stock Titan
Serina Therapeutics Inc. Rallies on Dynamic Market Expansion Prospects - timothysykes.com
Serina Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | 2BO | US81751A1088 - marketscreener.com
Stock Market Today: Futures Drop Ahead Of 'Triple Witching' Session As Iran Threatens 'Zero Restraint'— FedEx, Super Micro In Focus (UPDATED) - Benzinga
Serina Therapeutics (SER) Stock Jumps 39% Following $63M Financing Deal and Leadership Announcement - MEXC
Serina Therapeutics (SER) Stock Climbs 39% on Private Placement and Greg Bailey Appointment - MEXC
Biotech Microcap Rockets After Securing Major Capital Infusion at Premium Valuation - The Globe and Mail
SER Stock Surges Amid Strategic Acquisitions and Partnerships - StocksToTrade
Serina Therapeutics (SER) Stock Soars 39% After Announcing $63M Funding and Leadership Boost - parameter.io
Serina Therapeutics (SER) Stock Soars 39% After $30M Funding Deal and Leadership Boost - MoneyCheck
Serina Therapeutics’ Stock Hits All-Time Low Amid Financial Challenges - timothysykes.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Serina Therapeutics (SER) Stock Surges Over 39% After Hours— Here's Why - Benzinga
Dow Falls Over 300 Points; US Initial Jobless Claims Fall - Sahm
Serina Therapeutics, Inc. Appoints Greg Bailey as Co-Chairman of the Board of Directors - marketscreener.com
Serina Therapeutics Raises $30 Million in Private Placement - marketscreener.com
Parkinson's drug trial gets up to $30M as Serina adds board co-chair - Stock Titan
Macro Review: What is the dividend yield of Serina Therapeutics IncTrade Entry Report & Smart Investment Allocation Insights - baoquankhu1.vn
Serina Therapeutics, Inc. announced that it expects to receive $30 million in funding - marketscreener.com
Aug Swings: Is Serina Therapeutics Inc benefiting from innovation trends2026 Investor Takeaways & High Yield Stock Recommendations - baoquankhu1.vn
Aug Action: Does Serina Therapeutics Inc have declining or rising EPS2026 Earnings & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
How Serina Therapeutics Inc. stock reacts to inflationary pressuresJuly 2025 Technicals & Low Risk Growth Stock Ideas - Naître et grandir
How Serina Therapeutics Inc. stock benefits from global expansionJuly 2025 Chart Watch & Real-Time Buy Signal Alerts - Naître et grandir
Serina Therapeutics Advances SER-252 Parkinson’s Trial, Marking a Key Early Milestone for Investors - TipRanks
Entry Recap: Is Zillow Group Inc showing insider buying2025 Growth vs Value & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Serina Therapeutics Announces Dosing of First Patient in - GlobeNewswire
New drug SER-252 enters Phase 1b trial for advanced Parkinson's - Stock Titan
SER SEC FilingsSerina Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Serina Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Serina Begins Phase 1b Registrational Trial Of SER-252 In Advanced Parkinson's - Nasdaq
First patient enrolled in Serina’s Parkinson’s disease trial - Investing.com
Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease - The Manila Times
New Parkinson's trial enrolls first patient as Serina targets advanced disease - Stock Titan
SER PE Ratio & Valuation, Is SER Overvalued - Intellectia AI
Director Simba Gill granted 92,000 Serina Therapeutics (SER) stock options - Stock Titan
What are Serina Therapeutics Inc.’s recent SEC filings showingWeekly Loss Report & Fast Momentum Entry Tips - mfd.ru
Momentum Shift: Is CERo Therapeutics Holdings Inc likely to announce a buybackMarket Movers & High Accuracy Swing Trade Signals - baoquankhu1.vn
Aug Drivers: Whats next for Marchex Inc stockShort Setup & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Is Serina Therapeutics Inc. benefiting from interest rate changesTrade Performance Summary & Technical Entry and Exit Tips - mfd.ru
Will Serina Therapeutics Inc. stock outperform international peersJuly 2025 Big Picture & Expert Approved Momentum Trade Ideas - mfd.ru
Published on: 2026-02-05 05:58:49 - mfd.ru
Serina Therapeutics Inc Stock (SER) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.55%
0.19%
Cap:
|
Volume (24h):